Publication:
Mortality after Transplantation for Hepatocellular Carcinoma: A Study from the European Liver Transplant Registry.

dc.contributor.authorPommergaard, Hans-Christian
dc.contributor.authorRostved, Andreas Arendtsen
dc.contributor.authorAdam, René
dc.contributor.authorRasmussen, Allan
dc.contributor.authorSalizzoni, Mauro
dc.contributor.authorBravo, Miguel Angel Gómez
dc.contributor.authorCherqui, Daniel
dc.contributor.authorDe Simone, Paolo
dc.contributor.authorHoussel-Debry, Pauline
dc.contributor.authorMazzaferro, Vincenzo
dc.contributor.authorSoubrane, Olivier
dc.contributor.authorGarcía-Valdecasas, Juan Carlos
dc.contributor.authorProus, Joan Fabregat
dc.contributor.authorPinna, Antonio D
dc.contributor.authorO'Grady, John
dc.contributor.authorKaram, Vincent
dc.contributor.authorDuvoux, Christophe
dc.contributor.authorThygesen, Lau Caspar
dc.date.accessioned2023-02-09T09:42:28Z
dc.date.available2023-02-09T09:42:28Z
dc.date.issued2020-05-12
dc.description.abstractPrognosis after liver transplantation differs between hepatocellular carcinoma (HCC) arising in cirrhotic and non-cirrhotic livers and aetiology is poorly understood. The aim was to investigate differences in mortality after liver transplantation between these patients. We included patients from the European Liver Transplant Registry transplanted due to HCC from 1990 to November 2016 and compared cirrhotic and non-cirrhotic patients using propensity score (PS) calibration of Cox regression estimates to adjust for unmeasured confounding. We included 22,787 patients, of whom 96.5% had cirrhosis. In the unadjusted analysis, non-cirrhotic patients had an increased risk of overall mortality with a hazard ratio (HR) of 1.37 (95% confidence interval [CI] 1.23-1.52). However, the HR approached unity with increasing adjustment and was 1.11 (95% CI 0.99-1.25) when adjusted for unmeasured confounding. Unadjusted, non-cirrhotic patients had an increased risk of HCC-specific mortality (HR 2.62, 95% CI 2.21-3.12). After adjustment for unmeasured confounding, the risk remained significantly increased (HR 1.62, 95% CI 1.31-2.00). Using PS calibration, we showed that HCC in non-cirrhotic liver has similar overall mortality, but higher HCC-specific mortality. This may be a result of a more aggressive cancer form in the non-cirrhotic liver as higher mortality could not be explained by tumour characteristics or other prognostic variables.
dc.identifier.doi10.1159/000507397
dc.identifier.issn2235-1795
dc.identifier.pmcPMC7506266
dc.identifier.pmid32999871
dc.identifier.pubmedURLhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506266/pdf
dc.identifier.unpaywallURLhttps://www.karger.com/Article/Pdf/507397
dc.identifier.urihttp://hdl.handle.net/10668/16356
dc.issue.number4
dc.journal.titleLiver cancer
dc.journal.titleabbreviationLiver Cancer
dc.language.isoen
dc.organizationHospital Universitario Virgen del Rocío
dc.page.number455-467
dc.pubmedtypeJournal Article
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectCirrhosis
dc.subjectHepatocellular carcinoma
dc.subjectLiver transplantation
dc.subjectNon-cirrhotic liver
dc.subjectPrognosis
dc.subjectPropensity score calibration
dc.subjectUnmeasured confounding
dc.titleMortality after Transplantation for Hepatocellular Carcinoma: A Study from the European Liver Transplant Registry.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number9
dspace.entity.typePublication

Files